ReviewBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2011
Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach.
Review in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 12 citations in OpenAlex.
- Long-term outcome after autologous or allogeneic stem cell transplantation in patients with recurrent follicular lymphoma.Bone marrow transplantation · 2012Trial
- Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma.Experimental hematology · 2014Article
- Superior long-term outcome of patients with early transformation of non-Hodgkin lymphoma undergoing stem cell transplantation.Clinical lymphoma, myeloma & leukemia · 2012Article
- Primary central nervous system lymphoma: implication of high-dose chemotherapy followed by auto-SCT.Bone marrow transplantation · 2012Review
- Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies.Experimental hematology · 2012Article
- Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders.Revista brasileira de hematologia e hemoterapiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Transformed non-Hodgkin lymphoma (TL) arising from follicular lymphoma carries a poor prognosis, and the median survival time after transformation is approximately 10 to 12 months. Standard chemotherapy and radioimmunotherapy have offered promising responses; however, the duration of response does not appear to last long. Several studies evaluating the role of autologous stem cell transplantation (auto-SCT) as a salvage regimen have been reported, and a subset of patients benefit from this modality of treatment. With an improvement in supportive care, outcome after allogeneic stem cell transplantation (allo-SCT) has been improved significantly over past decades; however, very limited data are available for TL. In the era of emerging novel therapies, the actual timing, optimal conditioning regimens, and long-term impact of the type of stem cell transplantation (auto-SCT vs allo-SCT) is unclear. This review addresses the approaches to the management of patients with TL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.